2. Search Result
Search Result
Results for "

neurodevelopmental disorders

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119976
    Boscalid
    1 Publications Verification

    		 Environmental Pollutants Apoptosis Fungal Mitochondrial Metabolism Succinate Dehydrogenase Infection
    Boscalid is a succinate dehydrogenase (SDHI) inhibitor with antifungal activity. Boscalid binds to the ubiquinone-binding site of fungal mitochondrial complex II, blocks ATP production and aerobic respiration, exhibits good control efficacy against a variety of plant fungal diseases including gray mold, sclerotinia rot and powdery mildew, and is widely used for disease control in agriculture. Boscalid induces apoptosis, altered lipid metabolism, mitochondrial dysfunction, respiratory impairment, oxidative stress, ROS accumulation and neurodevelopmental disorders in zebrafish. Boscalid reduces foraging ability, shortens median death time and causes chronic toxicity in exposed honeybees. Boscalid also possesses genotoxicity, cytotoxicity, elevated mitochondrial superoxide levels and early-stage apoptosis .
    Boscalid
  • HY-148130
    Rugonersen

    RG6091; RO7248824

    		 E1/E2/E3 Enzyme Others
    Rugonersen (RG6091; RO7248824) is a locked-nucleic acid (LNA)- modified antisense oligonucleotides (ASOs), and results in reduction of ubiquitin-protein ligase E3A (UBE3A) silencing. Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, Rugonersen has been used for AS reasearch .
    Rugonersen
  • HY-138830
    TAK-418
    2 Publications Verification

    		 Histone Demethylase Neurological Disease
    TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models .
    TAK-418
  • HY-W002199
    6:2 Fluorotelomer alcohol

    6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol

    		 Bacterial Apoptosis ERK TNF Receptor Infection Neurological Disease
    6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of cyclin D1 and ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1 expression, upregulates ETS1 via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders .
    6:2 Fluorotelomer alcohol
  • HY-148130A
    Rugonersen sodium

    RG6091 sodium; RO7248824 sodium

    		 E1/E2/E3 Enzyme Others
    Rugonersen sodium is a locked-nucleic acid (LNA)- modified antisense oligonucleotides (ASOs), and results in reduction of ubiquitin-protein ligase E3A (UBE3A) silencing. Angelman syndrome (AS) sodium is a severe neurodevelopmental disorder caused by the loss of neuronal E3 ligase UBE3A, Rugonersen has been used for AS reasearch .
    Rugonersen sodium
  • HY-12520
    SKF 38393

    		Dopamine Receptor Neurological Disease Cancer
    SKF 38393 is a selective dopamine D1 receptor agonist. SKF 38393 activates the cAMP signaling pathway and promotes dopamine release in the developing rat striatum. SKF 38393 inhibits MCF-7 breast cancer cell proliferation (IC50=0.1 μM). SKF 38393 is promising for research of neurodevelopmental disorders, dopamine-related diseases (e.g., Parkinson’s, dopamine deficiency), and cancers .
    SKF 38393
  • HY-175807
    ppGalNAc-T2-IN-1

    		Others Neurological Disease Metabolic Disease
    ppGalNAc-T2-IN-1 (Compound 15) is a Polypeptide N-acetyl-galactosaminyltransferase 2 (ppGalNAc-T2) inhibitor with an IC50 of 7.11  μM. ppGalNAc-T2-IN-1 can be used for metabolic and neurodevelopmental disorders research .
    ppGalNAc-T2-IN-1
  • HY-120229
    GGTI-2147

    		Protein Prenyltransferase Neurological Disease
    GGTI-2147 is a potent GGTase I inhibitor. GGTI-2147 blocks geranyl-geranylation of Rap1A and reduces the activity of Rac1 (one of substrates for GGTI) and ameliorates the OGD/R-induced neuronal apoptosis.GGTI-2147 can be used for neurodevelopmental disorders research, such as autism, depression, and schizophrenia .
    GGTI-2147
  • HY-106769A
    (3aR,9aR)-Fluparoxan hydrochloride

    (3aR,9aR)-GR50360 hydrochloride

    		 Others Neurological Disease
    (3aR,9aR)-Fluparoxan ((3aR,9aR)-GR50360) hydrochloride is a compound that can be used to synthesize and prevent and improve neurodevelopmental disorders .
    (3aR,9aR)-Fluparoxan hydrochloride
  • HY-172127
    NUAK1-IN-1

    		AMPK CDK Neurological Disease Cancer
    NUAK1-IN-1 (Compound 9) is a NUAK1 (IC50 of 5.012 nM) and CDK4 inhibitor. NUAK1-IN-1 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research .
    NUAK1-IN-1
  • HY-172128
    NUAK1-IN-2

    		AMPK CDK Neurological Disease Cancer
    NUAK1-IN-2 (Compound 24) is a NUAK1 (IC50 of 3.162 nM) and CDK2/4/6 inhibitor. NUAK1-IN-2 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research .
    NUAK1-IN-2
  • HY-138830A
    (S,S)-TAK-418

    		Histone Demethylase Neurological Disease
    (S,S)-TAK-418 is a potent inhibitor of lysine-specific demethylase 1 (LSD1), demonstrating significant normalization of aberrant gene expression in neurodevelopmental disorders. (S,S)-TAK-418 also ameliorates ASD-like behaviors in rodent models affected by maternal exposure to valproate or poly I:C. (S,S)-TAK-418 modulates gene expression differently across various models and ages, indicating its potential as a therapeutic agent for conditions like autism spectrum disorder and schizophrenia.
    (S,S)-TAK-418
  • HY-106769B
    (3aR,9aR)-Fluparoxan

    (3aR,9aR)-GR50360

    		 Adrenergic Receptor Neurological Disease
    (3aR,9aR)-Fluparoxan ((3aR,9aR)-GR50360) is a highly selective and potent α2B adrenaline receptor antagonist with the activity of preventing, improving or inhibiting neurodevelopmental disorders and neurodegenerative diseases. As an α2B receptor antagonist, (3aR,9aR)-Fluparoxan can promote the recovery of neurological function. The mechanism of action of (3aR,9aR)-Fluparoxan makes it have important application potential in neuroscience research .
    (3aR,9aR)-Fluparoxan
  • HY-104044A
    Pamiparib maleate

    BGB-290 maleate

    		 Apoptosis Neurological Disease
    Pamiparib maleate (BGB-290 maleate) is a highly potent and selective PARP inhibitor with neurotoxicity-inducing activity. Pamiparib maleate can effectively penetrate the blood-brain barrier and cause cerebral hemorrhage, brain atrophy, and movement disorders in zebrafish embryos exposed. Pamiparib maleate exposure downregulates the activities of acetylcholinesterase (AChE) and adenosine triphosphatase (ATPase) and leads to upregulation of oxidative stress, which triggers apoptosis and interferes with the expression of neurodevelopment-related genes. The use of pamiparib maleate is also accompanied by downregulation of the Notch signaling pathway, while activation of the Notch signaling pathway can partially rescue neurodevelopmental toxicity. Therefore, pamiparib maleate provides a reference for evaluating its potential neurotoxicity during embryonic development .
    Pamiparib maleate
  • HY-119976S
    Boscalid-d4

    		Isotope-Labeled Compounds Apoptosis Fungal Mitochondrial Metabolism Succinate Dehydrogenase Others
    Boscalid-d4 is the deuterium labeled Boscalid. Boscalid is a succinate dehydrogenase (SDHI) inhibitor with antifungal activity. Boscalid binds to the ubiquinone-binding site of fungal mitochondrial complex II, blocks ATP production and aerobic respiration, exhibits good control efficacy against a variety of plant fungal diseases including gray mold, sclerotinia rot and powdery mildew, and is widely used for disease control in agriculture. Boscalid induces apoptosis, altered lipid metabolism, mitochondrial dysfunction, respiratory impairment, oxidative stress, ROS accumulation and neurodevelopmental disorders in zebrafish. Boscalid reduces foraging ability, shortens median death time and causes chronic toxicity in exposed honeybees. Boscalid also possesses genotoxicity, cytotoxicity, elevated mitochondrial superoxide levels and early-stage apoptosis .
    Boscalid-d4
  • HY-119976R
    Boscalid (Standard)

    		Reference Standards Apoptosis Fungal Mitochondrial Metabolism Succinate Dehydrogenase Infection
    Boscalid (Standard) is the analytical standard of Boscalid. This product is intended for research and analytical applications. Boscalid is a succinate dehydrogenase (SDHI) inhibitor with antifungal activity. Boscalid binds to the ubiquinone-binding site of fungal mitochondrial complex II, blocks ATP production and aerobic respiration, exhibits good control efficacy against a variety of plant fungal diseases including gray mold, sclerotinia rot and powdery mildew, and is widely used for disease control in agriculture. Boscalid induces apoptosis, altered lipid metabolism, mitochondrial dysfunction, respiratory impairment, oxidative stress, ROS accumulation and neurodevelopmental disorders in zebrafish. Boscalid reduces foraging ability, shortens median death time and causes chronic toxicity in exposed honeybees. Boscalid also possesses genotoxicity, cytotoxicity, elevated mitochondrial superoxide levels and early-stage apoptosis .
    Boscalid (Standard)
  • HY-181281
    VU6080195

    		Ser/Thr Kinase Neurological Disease Cancer
    VU6080195 is a blood-brain barrier-permeable pan-TAOK activator. VU6080195 shows the highest potency against TAOK1 (EC50 = 270 nM), followed by TAOK3 (EC50 = 503 nM) and TAOK2 (EC50 = 1,376 nM). VU6080195 can be used for the research of diseases such as neurodevelopmental disorders, tauopathies and breast cancer .
    VU6080195
  • HY-181280
    VU6083859

    		Ser/Thr Protease Neurological Disease
    VU6083859 is a blood-brain barrier-permeable TAOK1 inhibitor with an IC50 of 158 nM. VU6083859 selectively inhibits TAOK1, exhibits only weak or no activity against TAOK2 and TAOK3, and shows high selectivity for a variety of other kinases. VU6083859 is applicable to research related to neurodevelopmental disorders and tauopathies.
    VU6083859
  • HY-181552
    GABAA receptor modulator-13

    		GABA Receptor Neurological Disease
    GABAA receptor modulator-13 is an orally active, blood-brain barrier-permeable α4β1δ GABAA receptor modulator (IC50 = 9.02 μM). GABAA receptor modulator-13 reduces GABA-induced currents, impairs the stability of the transmembrane domain M2-M3 loop of α4β1δ GABAA receptors, and exhibits selectivity for γ2-containing GABAA receptor subtypes and α6β3δ GABAA receptor subtypes. GABAA receptor modulator-13 is applicable to the research of nervous system diseases with altered tonic inhibition, such as neurodevelopmental disorders and epilepsy .
    GABAA receptor modulator-13
  • HY-180779
    SR-1815

    		Ras Neurological Disease
    SR-1815 is a small molecule multi-kinase inhibitor. SR-1815, through mechanisms such as splicing regulation effectively restores the SynGAP protein to normal levels in the disease model with Syngap1 haploinsufficiency, thereby correcting the functional abnormalities at the synaptic and neuronal network levels caused by the deficiency of this gene. SR-1815 can be used for the study of brain diseases .
    SR-1815

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: